If you are a person in Arkansas with severe allergies, the EpiPen is more than a nice-to-have thing. If you are a parent of a child who could go into anaphylactic shock after exposure to a peanut, the issue could be the difference between life and death.
No wonder there has been such uproar in recent months over moves by the EpiPen’s maker to charge more for the epinephrine-delivery device. We aren’t talking a slight hike. As many news reports have noted, the cost of an EpiPen twin-pack has gone up 500 percent in the past ten years. For some families, that kind of increase for a must-have product is enough to thrust them into needing real debt relief.
Avenues for obtaining that help exist, but they can be difficult to consider and pursue in the midst of an anxiety attack. Speaking with an experienced attorney should be more than something to just consider. Action is called for.
The outcry over the price hikes by Mylan, the pharmaceutical company that owns the rights to the EpiPen is not surprising. And its tactics in response to the furor are being received skeptically by some.
The company announced this week that it will start selling a generic version of the drug for half the price of its main branded product. So, instead of the standard $600 cost, a twin-pack of the generic will be $300. As Time.com observed, it’s an old bargaining ploy. Create a situation where the initial offer is outlandish. When you capitulate with a lower offer, it seems relatively reasonable. But the outcome is not that much different.
Many reasons can be floated as to why medical costs are as high as they are. They mean little to the consumer who winds up on the receiving end of the bill. If you find yourself needing debt relief help because of large medical bills, seek help from a skilled attorney.
Source: Time.com, “Why the Generic EpiPen Still Doesn’t Solve the Problem,” Haley Sweetland Edwards, Aug. 29, 2016